5/5/2025
Last update
5/5/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.4
USERS' SCORE
Good
Based on 6 Reviews
8.2
Supplement Facts
Serving Size: 2 Marine Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Fish Oil ConcentrateTotal Omega-3 Fatty Acids as Ethyl EstersEPA (EicosaPentaenoic Acid), min.DHA (DocosaHexaenoic Acid), min.
2000 mg1400 mg800 mg400 mg
††††
Top Medical Research Studies
9
Omega-3s' mixed effects on heart health
We examined the impact of omega-3 fatty acids, often found in fish oil, on heart attack risks, particularly in patients with high triglyceride levels. The studies indicate that while omega-3s can effectively lower triglycerides and reduce certain cardiovascular disease outcomes, including fatal heart attacks, their overall benefit remains debated. Despite extensive research demonstrating some positive outcomes, many experts still question the magnitude of their effects on heart attack prevention. Improved guidance on omega-3 supplementation is still evolving as new evidence emerges.
8
Omega-3 reduces heart attack risk
We explored the impact of omega-3 fatty acids on heart attack risk, focusing on African Americans. In a study analyzing data from the VITAL trial, we matched African American participants with non-Hispanic White individuals to simulate a randomized controlled trial.
Surprisingly, our findings indicated that omega-3 supplementation significantly decreased heart attack risk in African Americans but showed no benefit for non-Hispanic Whites. This highlights the importance of addressing racial differences in how individuals respond to omega-3 fish oil, urging further research in this area.
Surprisingly, our findings indicated that omega-3 supplementation significantly decreased heart attack risk in African Americans but showed no benefit for non-Hispanic Whites. This highlights the importance of addressing racial differences in how individuals respond to omega-3 fish oil, urging further research in this area.
8
We delved into how different types of fatty acids influence the risk of coronary heart disease (CHD) using data from a large study of over 89,000 adults.
Our findings revealed that omega-3 fatty acids seemed to lower the risk of CHD, standing out among other fatty acids. Interestingly, saturated and monounsaturated fats did show a positive link to CHD, but this was largely connected to their effect on triglyceride levels.
Overall, omega-3 fatty acids might offer a protective benefit against heart disease.
Our findings revealed that omega-3 fatty acids seemed to lower the risk of CHD, standing out among other fatty acids. Interestingly, saturated and monounsaturated fats did show a positive link to CHD, but this was largely connected to their effect on triglyceride levels.
Overall, omega-3 fatty acids might offer a protective benefit against heart disease.
Most Useful Reviews
9
Balances hormones
3 people found this helpful
I completely trust this brand after years of usage. Omega 3 has helped me restore my health, balancing hormones, alleviating hair issues, and providing heart support, as confirmed by my doctor. The benefits are incredible and the packaging is adequate, making it a great value.
7.5
Improves immunity
2 people found this helpful
The quality of this Omega supplement is astounding. My immunity has gradually improved, my hair is now shiny, and there’s no fishy odour. Noticeably, I feel less tired while climbing stairs, indicating a significant difference in my heart health.
7.5
Helps maintain BP
2 people found this helpful
I take this every morning for heart health. Having used it for several years, at 72, my systolic BP is under 130, and I have no heart-related health issues. While I can't confirm that it's solely due to fish oil capsules, I plan to continue using them as a preventive measure.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.4
- All Researches
9
Omega-3s' mixed effects on heart health
We examined the impact of omega-3 fatty acids, often found in fish oil, on heart attack risks, particularly in patients with high triglyceride levels. The studies indicate that while omega-3s can effectively lower triglycerides and reduce certain cardiovascular disease outcomes, including fatal heart attacks, their overall benefit remains debated. Despite extensive research demonstrating some positive outcomes, many experts still question the magnitude of their effects on heart attack prevention. Improved guidance on omega-3 supplementation is still evolving as new evidence emerges.
9
We explored whether icosapent ethyl (IPE), a refined omega-3 fatty acid, could lower heart attack risk among cigarette smokers. In the REDUCE-IT trial, over 8,000 statin-treated patients were randomly assigned to receive either IPE or a placebo for nearly five years.
Our findings showed that IPE significantly reduced cardiovascular events by 25%, especially for current and former smokers. Participants using IPE experienced heart attack rates similar to non-smokers, suggesting that IPE may help lessen cardiovascular risks associated with smoking.
Our findings showed that IPE significantly reduced cardiovascular events by 25%, especially for current and former smokers. Participants using IPE experienced heart attack rates similar to non-smokers, suggesting that IPE may help lessen cardiovascular risks associated with smoking.
9
We examined the effects of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on the risk of heart attacks through a comprehensive analysis of the VITAL trial. This significant study included nearly 26,000 older adults in the U.S. who were monitored over an average of 5.3 years.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
The original trial didn't find significant results for major cardiovascular events overall, but our Bayesian analysis suggested a different insight. By incorporating previous research and evidence, we discovered that daily supplementation with EPA appears to notably lower the risk of coronary heart disease events, particularly heart attacks.
However, the same beneficial effects did not extend to strokes or overall cardiovascular death, which means while we do see an encouraging trend for heart attacks, the evidence doesn't support a broad impact on other cardiovascular-related issues. Our findings help reinforce the value of omega-3 fatty acid supplementation as a preventive measure specifically for heart attacks.
9
We explored the role of eicosapentaenoic acid (EPA) in heart attack recovery, particularly its effect on restoring blood flow during ST-elevation myocardial infarction (STEMI). Our focus was on understanding whether higher levels of EPA relative to arachidonic acid could lead to faster recovery and better outcomes for patients experiencing this type of heart attack.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
The study revealed that patients with elevated EPA levels indeed showed quicker restoration of coronary blood flow. This is promising, as efficient blood flow restoration is critical in minimizing heart damage during a heart attack. However, it’s essential to note that the effectiveness of EPA may vary based on other treatments the patients are receiving.
These findings suggest a positive link between EPA and heart attack recovery, but further investigation is necessary to determine the best approaches for integrating EPA into treatment protocols. Ultimately, while we observed encouraging results, the interplay between dietary interventions and other medical treatments warrants additional research.
9
We explored how eicosapentaenoic acid (EPA) and its metabolites can protect heart cells during a heart attack, specifically focusing on a laboratory model for ischemic injury. Our investigation centered on a specific receptor found in heart cells, known as the Free Fatty Acid Receptor 4 (Ffar4).
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
In our experiments, cardiac myocytes, or heart cells, were exposed to a controlled environment mimicking conditions of reduced blood flow followed by reoxygenation, essentially simulating a heart attack scenario. Applying an Ffar4 agonist, TUG-891, along with EPA-derived components like 18-hydroxyeicosapentaenoic acid (18-HEPE) and resolvin E1 (RvE1), we observed a significant reduction in harmful reactive oxygen species and heart cell death.
Notably, blocking the ChemR23 receptor with a specific antagonist negated the protective effects we noted from these treatments. This finding highlights that Ffar4 and ChemR23 work together in heart cells to defend against the damage that occurs after ischemic injury.
Overall, our data reinforce the idea that eicosapentaenoic acid has beneficial roles in protecting heart cells from ischemia, meriting further exploration as a potential therapeutic in heart attack management.
User Reviews
USERS' SCORE
Good
Based on 6 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Balances hormones
3 people found this helpful
I completely trust this brand after years of usage. Omega 3 has helped me restore my health, balancing hormones, alleviating hair issues, and providing heart support, as confirmed by my doctor. The benefits are incredible and the packaging is adequate, making it a great value.
7.5
Improves immunity
2 people found this helpful
The quality of this Omega supplement is astounding. My immunity has gradually improved, my hair is now shiny, and there’s no fishy odour. Noticeably, I feel less tired while climbing stairs, indicating a significant difference in my heart health.
7.5
Helps maintain BP
2 people found this helpful
I take this every morning for heart health. Having used it for several years, at 72, my systolic BP is under 130, and I have no heart-related health issues. While I can't confirm that it's solely due to fish oil capsules, I plan to continue using them as a preventive measure.
9
Excellent dosage
The dose is 1000 mg and the quality is excellent. This is the best option for health and cholesterol management; the heart will certainly appreciate it.
7.5
Supports heart health
I take Omega 3 due to its significance for heart health, particularly since I lead a sedentary lifestyle, and it aids in alleviating arthritis caused by knee roughness.
Frequently Asked Questions
7.5
Improves immunity
2 people found this helpful
The quality of this Omega supplement is astounding. My immunity has gradually improved, my hair is now shiny, and there’s no fishy odour. Noticeably, I feel less tired while climbing stairs, indicating a significant difference in my heart health.
7.5
Helps maintain BP
2 people found this helpful
I take this every morning for heart health. Having used it for several years, at 72, my systolic BP is under 130, and I have no heart-related health issues. While I can't confirm that it's solely due to fish oil capsules, I plan to continue using them as a preventive measure.
9
Balances hormones
3 people found this helpful
I completely trust this brand after years of usage. Omega 3 has helped me restore my health, balancing hormones, alleviating hair issues, and providing heart support, as confirmed by my doctor. The benefits are incredible and the packaging is adequate, making it a great value.
9
Excellent dosage
The dose is 1000 mg and the quality is excellent. This is the best option for health and cholesterol management; the heart will certainly appreciate it.
7.5
Supports heart health
I take Omega 3 due to its significance for heart health, particularly since I lead a sedentary lifestyle, and it aids in alleviating arthritis caused by knee roughness.
6
Supportive heart product
Top quality product for reducing cholesterol and inflammation, supporting heart health.
8
Omega-3 improves heart attack outcomes
We observed that icosapent ethyl, a type of omega-3 fish oil, plays a significant role in reducing heart attack risk among patients with atherosclerotic cardiovascular disease (ASCVD). In a study involving almost 5,800 participants, those taking icosapent ethyl experienced lower rates of major adverse cardiovascular events (MACE) compared to those on placebo.
The treatment showed effectiveness across all levels of cardiovascular risk, particularly benefiting those at higher risk. Overall, this suggests that incorporating icosapent ethyl could be an important option for managing heart attack risks.
The treatment showed effectiveness across all levels of cardiovascular risk, particularly benefiting those at higher risk. Overall, this suggests that incorporating icosapent ethyl could be an important option for managing heart attack risks.
9
Eicosapentaenoic acid reduces heart attack risk
We explored the impact of eicosapentaenoic acid (EPA) treatment on heart attack risk, particularly in patients with high cardiovascular (CV) risk who are already on statin therapy. The evidence we reviewed highlights that icosapent ethyl (IPE), a pure form of EPA, is particularly effective in reducing the risk of serious CV events.
In clinical trials, like the REDUCE-IT study, we observed a remarkable 25% decrease in CV events for patients taking IPE compared to those who were not. This included significant outcomes like reducing the chances of heart attacks, strokes, and hospitalization for unstable angina. Importantly, this benefit was consistent across various groups of patients—regardless of their initial triglyceride levels or whether they had conditions like type 2 diabetes.
While some patients experienced adverse effects like atrial fibrillation, these were mostly in individuals with a history of the condition. The overall clinical benefit of IPE far surpassed the potential risks. Moreover, combining IPE with other omega-3 treatments often diluted its effectiveness, which emphasizes the uniqueness of EPA alone.
Ultimately, adding IPE to statin treatments appears to not only enhance patient outcomes but also offers a cost-effective strategy in managing heart disease, particularly in secondary prevention efforts. This reinforces the growing recognition of IPE as an essential component in tackling high cholesterol and CV risk.
In clinical trials, like the REDUCE-IT study, we observed a remarkable 25% decrease in CV events for patients taking IPE compared to those who were not. This included significant outcomes like reducing the chances of heart attacks, strokes, and hospitalization for unstable angina. Importantly, this benefit was consistent across various groups of patients—regardless of their initial triglyceride levels or whether they had conditions like type 2 diabetes.
While some patients experienced adverse effects like atrial fibrillation, these were mostly in individuals with a history of the condition. The overall clinical benefit of IPE far surpassed the potential risks. Moreover, combining IPE with other omega-3 treatments often diluted its effectiveness, which emphasizes the uniqueness of EPA alone.
Ultimately, adding IPE to statin treatments appears to not only enhance patient outcomes but also offers a cost-effective strategy in managing heart disease, particularly in secondary prevention efforts. This reinforces the growing recognition of IPE as an essential component in tackling high cholesterol and CV risk.
8
We investigated how levels of omega-3 fatty acids in body fat relate to heart attack risk. Analyzing samples from 3,500 participants over 15 years, we found that both omega-3 fractions and their ratios to omega-6 fatty acids were linked to a lower chance of heart attacks. However, the ratios of omega-3 to omega-6 were better predictors of heart attack risks. This suggests that adjusting our diets to enhance these ratios could be beneficial for reducing heart attack risk in the population.
7
Omega-3 and statin heart benefits
We examined the effects of adding omega-3 fatty acids to statin therapy for heart health by reviewing 14 randomized controlled trials with about 40,991 patients. Our analysis showed that this combination significantly reduced events like heart attacks, unstable angina, and cholesterol levels compared to statins alone.
However, we found no major differences in deadly strokes or coronary surgeries. This suggests that while omega-3 supplementation may offer some benefits, it doesn't dramatically impact all cardiovascular outcomes.
However, we found no major differences in deadly strokes or coronary surgeries. This suggests that while omega-3 supplementation may offer some benefits, it doesn't dramatically impact all cardiovascular outcomes.
8
Omega-3 reduces heart attack risk
We explored the impact of omega-3 fatty acids on heart attack risk, focusing on African Americans. In a study analyzing data from the VITAL trial, we matched African American participants with non-Hispanic White individuals to simulate a randomized controlled trial.
Surprisingly, our findings indicated that omega-3 supplementation significantly decreased heart attack risk in African Americans but showed no benefit for non-Hispanic Whites. This highlights the importance of addressing racial differences in how individuals respond to omega-3 fish oil, urging further research in this area.
Surprisingly, our findings indicated that omega-3 supplementation significantly decreased heart attack risk in African Americans but showed no benefit for non-Hispanic Whites. This highlights the importance of addressing racial differences in how individuals respond to omega-3 fish oil, urging further research in this area.
References
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Sun S, Hara A, Johnstone L, Hallmark B, Watkins JC, et al. Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation. Nutrients. 2024;16. 10.3390/nu16172933
- Ahmadi M, Askari VR, Shahri B, Mousavi Noghab SM, Jarahi L, et al. Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:881. 10.1007/s00210-024-03330-1
- Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, et al. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. Eur Heart J Cardiovasc Pharmacother. 2024;10:488. 10.1093/ehjcvp/pvae030
- Bernhard B, Heydari B, Abdullah S, Francis SA, Lumish H, et al. Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial. Int J Cardiol. 2024;399:131698. 10.1016/j.ijcard.2023.131698
- Irfan A, Haider SH, Nasir A, Larik MO, Naz T. Assessing the Efficacy of Omega-3 Fatty Acids + Statins vs. Statins Only on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of 40,991 Patients. Curr Probl Cardiol. 2024;49:102245. 10.1016/j.cpcardiol.2023.102245
- Ogata S, Manson JE, Kang JH, Buring JE, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes. Nutrients. 2023;15. 10.3390/nu15194235
- Jin D, Trichia E, Islam N, Lewington S, Lacey B. Associations of circulating fatty acids with incident coronary heart disease: a prospective study of 89,242 individuals in UK Biobank. BMC Cardiovasc Disord. 2023;23:365. 10.1186/s12872-023-03394-6
- Lyytinen AT, Yesmean M, Manninen S, Lankinen M, Bhalke M, et al. Fatty fish consumption reduces lipophilic index in erythrocyte membranes and serum phospholipids. Nutr Metab Cardiovasc Dis. 2023;33:1453. 10.1016/j.numecd.2023.04.011
- Chiusolo S, Bork CS, Gentile F, Lundbye-Christensen S, Harris WS, et al. Adipose tissue n-3/n-6 fatty acids ratios versus n-3 fatty acids fractions as predictors of myocardial infarction. Am Heart J. 2023;262:38. 10.1016/j.ahj.2023.03.019
- Kobara M, Shiraishi T, Noda K, Toba H, Nakata T. Eicosapentaenoic Acid Preserves Mitochondrial Quality and Attenuates Cardiac Remodeling After Myocardial Infarction in Rats. J Cardiovasc Transl Res. 2023;16:816. 10.1007/s12265-023-10363-z
- Rodriguez D, Lavie CJ, Elagizi A, Milani RV. Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health. Nutrients. 2022;14. 10.3390/nu14235146
- Bassuk SS, Manson JE. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence. Cardiovasc Res. 2023;119:1297. 10.1093/cvr/cvac172
- Nishizaki Y, Miyauchi K, Iwata H, Inoue T, Hirayama A, et al. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2023;257:1. 10.1016/j.ahj.2022.11.008
- Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. 2023;9:129. 10.1093/ehjcvp/pvac045
- Yokoyama Y, Kuno T, Morita SX, Slipczuk L, Takagi H, et al. Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Cardiol. 2022;80:416. 10.1016/j.jjcc.2022.07.008
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Yamada R, Uematsu M, Nakamura T, Kobayashi T, Horikoshi T, et al. Elevated eicosapentaenoic acid to arachidonic acid ratio and rapid coronary blood flow restoration in ST-elevation myocardial infarction. Hellenic J Cardiol. 2025. 10.1016/j.hjc.2025.01.003
- Puccini SJ, Healy CL, Harsch BA, Ahmed AR, Shearer GC, et al. A Cell Autonomous Free fatty acid receptor 4 - ChemR23 Signaling Cascade Protects Cardiac Myocytes from Ischemic Injury. bioRxiv. 2025. 10.1101/2024.11.26.625260
- Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. 10.1161/CIRCULATIONAHA.123.065520
- Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31:1863. 10.1093/eurjpc/zwae184
- Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024;83:1529. 10.1016/j.jacc.2024.02.016
- Sabbour H, Bhatt DL, Elhenawi Y, Aljaberi A, Bennani L, et al. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovasc Drugs Ther. 2024. 10.1007/s10557-023-07519-z
- Le VT, Knight S, Watrous JD, Najhawan M, Dao K, et al. Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Front Cardiovasc Med. 2023;10:1229130. 10.3389/fcvm.2023.1229130
- Myhre PL, Berge T, Kalstad AA, Tveit SH, Laake K, et al. Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial. Clin Nutr. 2023;42:1657. 10.1016/j.clnu.2023.07.002
- Borghi C, Bragagni A. Clinical results and mechanism of action of icosapent ethyl. Eur Heart J Suppl. 2023;25:B37. 10.1093/eurheartjsupp/suad088
- Rabbat MG, Lakshmanan S, Benjamin MM, Doros G, Kinninger A, et al. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Heart J Cardiovasc Imaging. 2023;24:866. 10.1093/ehjci/jead063
